Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

NCT03104491 is registered in ClinicalTrials.gov with Leland Metheny as lead sponsor.

NCT NCT03104491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03104491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Lead sponsor
Leland Metheny
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 31, 2017
Completion date
May 31, 2027
Enrollment
44 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukemia